Ligand director granted RSUs and stock options
Ligand Pharmaceuticals director Nancy Ryan Gray received new equity awards.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Ligand Pharmaceuticals director Nancy Ryan Gray received new equity awards. She was granted 836 restricted stock units of common stock, which fully vest on the earlier of the next annual stockholder meeting or the first anniversary of the June 5, 2026 grant date.
Gray was also granted a non-qualified stock option for 2,938 shares of common stock at an exercise price of $237.00 per share, expiring on June 5, 2036. Following these grants, she holds 8,930 shares of common stock directly and 2,938 outstanding stock options.
Insider Trade Summary
Grant/Award: 3,774 shares
Grant/Award
2 txns
Insider
Gray Nancy Ryan
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Non-Qualified Stock Option (right to buy) | 2,938 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 836 | $0.00 | $0.00 |
Holdings After Transaction:
Non-Qualified Stock Option (right to buy) — 2,938 contracts (Direct);
Common Stock — 8,930 shares (Direct)
Footnotes (2)
- F1. Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 5, 2026. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.
- F2. Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 5, 2026. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.
Key Figures
RSUs granted: 836 units
Option shares granted: 2,938 shares
Option exercise price: $237.00 per share
+3 more
6 metrics
RSUs granted
836 units
Restricted stock units granted June 5, 2026
Option shares granted
2,938 shares
Non-qualified stock option granted June 5, 2026
Option exercise price
$237.00 per share
Non-qualified stock option strike price
Option expiration
June 5, 2036
Non-qualified stock option expiry date
Shares held after grant
8,930 shares
Common stock directly held following awards
Options held after grant
2,938 options
Non-qualified options outstanding after grant
Key Terms
restricted stock units, RSUs, Non-Qualified Stock Option, Board of Directors, +1 more
5 terms
restricted stock units financial
"Represents restricted stock units ("RSUs"). Each RSU represents a contingent right"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
RSUs financial
"Represents restricted stock units ("RSUs"). Each RSU represents a contingent right"
RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.
Non-Qualified Stock Option financial
"Non-Qualified Stock Option (right to buy)"
A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.
Board of Directors financial
"Acquired by a grant of the Board of Directors of the Company"
The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.
annual meeting financial
"grant of the Board of Directors of the Company at their annual meeting"
A company's annual meeting is a yearly gathering where owners (shareholders) and the board review performance, ask questions, and vote on key matters like electing directors, approving auditor choices, and sometimes setting pay or dividend policies. For investors it matters because decisions made and votes cast can change who runs the company, influence strategy and payouts, and affect the value or direction of their investment—similar to a homeowners’ meeting where rules and leaders that shape your property’s value are decided.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Nancy Ryan Gray acquire in this Ligand (LGND) Form 4 filing?
Nancy Ryan Gray received 836 restricted stock units and a non-qualified stock option for 2,938 shares at $237.00 per share. These equity awards were granted as director compensation at the June 5, 2026 annual meeting.
How do the RSUs granted to Nancy Ryan Gray at Ligand (LGND) vest?
The 836 restricted stock units fully vest on the earlier of the next Ligand annual stockholder meeting or the first anniversary of the June 5, 2026 grant date. Each RSU converts into one share of Ligand common stock upon vesting.
What are the key terms of Nancy Ryan Gray’s stock option grant at Ligand (LGND)?
Nancy Ryan Gray received a non-qualified stock option for 2,938 shares of Ligand common stock with a $237.00 exercise price. The option was granted June 5, 2026 and expires on June 5, 2036, providing long-term potential equity exposure.
Is Nancy Ryan Gray’s Ligand (LGND) Form 4 a purchase or an award?
The Form 4 reports compensation-related awards, not open-market purchases. Nancy Ryan Gray acquired 836 restricted stock units and an option for 2,938 shares, both granted by Ligand’s Board of Directors as part of her service as a director.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates